Media visibility and costs of new medicines under examination—what does the media highlight?

A study conducted by the University of Eastern Finland and Fimea found that the Finnish news media has given GLP-1 agonists used to treat obesity, such as semaglutide, a great deal of attention while many other new medicines have been ignored. Based on preliminary results, media visibility is not evenly divided between medicines intended for different indications, and the amount of visibility does not always correspond to such things as the user-specific costs of medicines or the prevalence of indications.

👉 Full Story